CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 499 enrolled
Drug / intervention
Prostate artery embolizationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03527589
NCT03527589N/ACompleted
CompareCT.gov

A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres

Merit Medical Systems, Inc.·observational·Posted May 17, 2018·Updated Dec 18, 2023

In Brief

An observational study evaluating Prostate artery embolization for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. Completed, enrolled 499 participants across 15 sites in 4 countries.

Detailed Summary

Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The goal of this post market study is to evaluate long-term safety and effectiveness in a 'real world' setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
CountriesFrance, Italy, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 17, 2018
Enrollment StartAug 16, 2018
Primary CompletionJan 21, 2020
Study CompletionJan 22, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.1 years ago

Interventions

Prostate artery embolizationdevice

Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.